RxDoctor Payments Data

Hemant Painter, MD

Geriatric Medicine · Orlando, FLNPI 1598741928

Payments from drug & device makers

$1,377in general payments, 2019–2025

Across 20 payments — averaging $68.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$710
  • Novo Nordisk$382
  • Otsuka America Pharmaceutical, Inc.$122
  • Edwards Lifesciences$101
  • Johnson & Johnson$45
  • Takeda Pharmaceuticals U.S.A., Inc.$17

What the payments were for

  • Food & beverage$1,375100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,377 in reported general payments places this provider in the 75th percentile of 305 geriatric medicine providers in Florida.

See all geriatric medicine providers in Florida

Medicare billing

Part B allowed, 2024
$165,750
Medicare patients
193
Services billed
1,565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban143$72,383
FarxigaDapagliflozin Propanediol67$47,580
JanuviaSitagliptin Phosphate33$23,538
JardianceEmpagliflozin36$18,079
XareltoRivaroxaban30$14,944
TradjentaLinagliptin31$11,909
GemtesaVibegron37$10,760
Sevelamer Hcl19$9,844
MyrbetriqMirabegron25$6,595
Advair HfaFluticasone Propion/Salmeterol14$6,179
DapagliflozinDapagliflozin Propanediol16$4,785
Atorvastatin Calcium344$4,690
LumiganBimatoprost14$3,722
Levothyroxine Sodium224$2,947
Memantine Hcl62$2,912

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$710$47,58067 claims
Johnson & JohnsonXarelto$45$14,94430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 305 geriatric medicine providers in Florida.

Other geriatric medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →